Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genentech (NYSE:DNA) formerly known as (NYSE:GNE) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (76)	11/9/2005 1:11:03 PM
From: west57th	Read Replies (1) \| Respond to of 250

Data showed 94% and 96% stable or improved vision on different Lucentis doses. Do we know how many were stable vs improved. If most were just stable (0-15 letters improvement) this would be a disappointment compared to earlier data. Later in the release they said "average patient improved". Does this mean improved in the technical definition of 15 letter improvement or is this meant in a more offhand way and stable patients are being lumped into the improved group. Stable will get this approved. But only a good chunk of patients improving will allow it to lock up the wet AMD space.